via HackerEarth Blog
Drug discovery could be significantly accelerated thanks to a new high precision machine-learning model, developed by an international collaboration of researchers, including the University of Warwick.
The algorithm – partly devised by Dr James Kermode from Warwick’s School of Engineering – can accurately predict the interactions between a protein and a drug molecule based on a handful of reference experiments or simulations.
Using just a few training references, it can predict whether or not a candidate drug molecule will bind to a target protein with 99% accuracy.
This is equivalent to predicting with near-certainty the activity of hundreds of compounds after actually testing them – by running only a couple dozen tests. The new method could accelerate the screening of candidate molecules thousands of times over.
The algorithm can also tackle materials-science problems such as modelling the subtle properties of silicon surfaces, and promises to revolutionise materials and chemical modelling – giving insight into the nature of intermolecular forces.
The approach, developed by scientists at the University of Warwick, the École polytechnique fédérale de Lausanne’s Laboratory of Computational Science and Modelling, the University of Cambridge, the UK Science and Technology Facilities Council and the U.S. Naval Research Laboratory, can also identify which parts of the molecules are crucial for the interaction.
Dr James Kermode, from the University of Warwick’s Warwick Centre for Predictive Modelling and the School of Engineering, commented on the research:
“This work is exciting because it provides a general-purpose machine learning approach that is applicable both to materials and molecules.
“The research is expected to lead to a significant increase in the accuracy and transferability of models used for drug design and to describe the mechanical properties of materials.”
The design of this algorithm, which combines local information from the neighbourhood of each atom in a structure, makes it applicable across many different classes of chemical, materials science, and biochemical problems.
The approach is remarkably successful in predicting the stability of organic molecules, as well as the subtle energy balance governing the silicon structures crucial for microelectronic applications, and does so at a tiny fraction of the computational effort involved in a quantum mechanical calculation.
The research illustrates how chemical and materials discovery is now benefitting from the Machine Learning and Artificial Intelligence approaches that already underlie technologies from self-driving cars to go-playing bots and automated medical diagnostics.
New algorithms allow us to predict the behaviour of new materials and molecules with great accuracy and little computational effort, saving time and money in the process.
Learn more: Drug discovery could accelerate hugely with Machine Learning
The Latest on: Drug discovery with machine learning
- Alchemab Announces Publication of AntiBERTa, an Antibody-Specific Machine Learning Model with Multiple Applicationson May 19, 2022 at 4:02 am
Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies and immune repertoire-based patient stratification tools, today ...
- PostEra spearheads AI-driven drug discovery collaboration to develop antiviral therapeutics with initial $68M in NIH fundingon May 18, 2022 at 11:00 pm
PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced a multi-year collaboration with ...
- Attend ‘AI and Machine Learning in Biomedical Research’ on May 24on May 18, 2022 at 6:35 am
Biomedical researchers with expertise in data science will discuss impact of artificial intelligence and machine learning on biomedical research, how it is being used for new and paradigm-shifting ...
- Predictive Oncology has an AI-driven drug discovery platform to improve cancer treatments and speed up drug developmenton May 12, 2022 at 11:36 am
“PeDAL provides an AI machine learning platform to drive experimental testing (coupled with tumor assay capabilities) to evaluate hundreds of diverse tumor samples against hundreds of drug compounds ...
- Outlook on the AI-based Drug Discovery Global Market to 2035 - Industry Trends and Forecastson May 12, 2022 at 3:03 am
The "AI-based Drug Discovery Market: Distribution by Drug Discovery Steps, Therapeutic Area and Key Geographies: Industry Trends and Global Forecasts, 2022-2035" report has been added to ...
- Drug Discovery for Neglected Tropical Diseases in the Era of Big Dataon May 10, 2022 at 12:06 am
The objective of this Research Topic is to bring recent advances in the application of in silico methods for the design and discovery ... Drug Design • Virtual Screening • Quantitative ...
- Applied BioMath, LLC to Present on Machine Learning in Drug Discovery at Bio-IT World Conference and Expoon April 27, 2022 at 12:14 pm
CONCORD, Mass., April 27, 2022 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help ...
- Applied BioMath, LLC to Present on Machine Learning in Drug Discovery at Bio-IT World Conference and Expoon April 27, 2022 at 11:32 am
Kas Subramanian, PhD, Executive Director of Modeling at Applied BioMath will present "Applications of Machine Learning in Preclinical Drug Discovery" within the conference track, AI for Drug ...
via Google News and Bing News